Evolus reports Q3 results, cuts expense guidance and reaffirms 2026‑2028 revenue targets
Evolus posted third‑quarter 2026 revenue of $77.95 million, a 13% year‑over‑year increase, while its net loss narrowed to $12.52 million and EPS loss was $0.19. The company lowered its full‑year non‑GAAP operating expense outlook to $210 million‑$213 million and reiterated its 2028 revenue goal of $450 million‑$500 million, with adjusted EBITDA margins of 13%‑15%. Management also reaffirmed 2026 revenue guidance of $330 million‑$337 million and said the FDA is expected to approve its Sculpt product in Q4 2026 for a 2027 launch.
Why it matters
The expense reduction and reaffirmed revenue targets suggest tighter cost control and sustained growth, which could improve future profitability expectations (the company’s guidance). The pending FDA approval for Sculpt adds a potential new revenue stream in 2027, influencing investors’ outlook for the company’s pipeline.
Key facts
- 1Q3 2026 revenue was $77.95 million, up 13% YoY. tradingview.com
- 2Net loss for the quarter was $12.52 million. tradingview.com
- 3EPS loss was $0.19. tradingview.com
- 4Full‑year non‑GAAP operating expense guidance was cut to $210 million‑$213 million, from $212 million‑$216 million. finance.yahoo.com
- 52028 revenue target was reaffirmed at $450 million‑$500 million. finance.yahoo.com
- 6Adjusted EBITDA margin guidance for 2028 is 13%‑15%. finance.yahoo.com
Summary written by AlphAI AI Desk from 3 of 3 sources. Not investment advice. Figures are as stated by the linked sources.